Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CO
Cosmos Holdings Inc. Common Stock
COSM
Mkt Cap
$33.3M
Volume
1.84M
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CO
COSM
CO
Cosmos Holdings Inc. Common Stock
COSM
News
·
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
Mkt Cap
$33.3M
Volume
1.84M
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
Cosmos Health Inc. (NASDAQ: COSM) announced a non-binding letter of intent to acquire 100% of Doc Pharma S.A., a European GMP-licensed pharmaceutical manufacturer. The acquisition is expected to be immediately accretive, expanding Cosmos Health's asset base by approximately $24 million, adding $6.7 million in average annual revenue and $3.2 million in gross profit. The deal aims to deepen vertical integration, improve margins, expand production capacity, and strengthen the company's R&D capabilities. The transaction is subject to independent director review, fairness opinion, and shareholder approval.
Benzinga · Jun 11, 2026
Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility
Cosmos Health Inc. purchased an additional $500,000 in Ethereum, bringing its total investment to $1.5 million under its $300 million digital assets facility, aiming to diversify its balance sheet and explore blockchain technology in healthcare.
GlobeNewswire Inc. · Oct 10, 2025
Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units
Cosmos Health's subsidiary SkyPharm signed an exclusive distribution agreement with Diyar United to market Sky Premium Life nutraceuticals in Kuwait, securing an initial purchase order of over 65,000 units in a market projected to reach $1.68 billion by 2030.
GlobeNewswire Inc. · Oct 3, 2025
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
Cosmos Health enters the U.S. nutraceuticals market with its Sky Premium Life brand, launching NOOR Collagen and expecting 75% gross margins and over $12M in annualized revenue from the product.
GlobeNewswire Inc. · Sep 22, 2025
Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
Cosmos Health signed a distribution agreement with Scientific Pharmacy in Oman for Sky Premium Life food supplements, securing an initial purchase order of 42,000 units in the rapidly growing $7 billion GCC nutraceuticals market.
GlobeNewswire Inc. · Sep 11, 2025
Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025
Cosmos Health reported Q2 2025 financial results with 11.7% revenue increase, gross profit up 53% to $3.21M in H1 2025, and continued progress towards profitability targets while expanding digital asset strategy.
GlobeNewswire Inc. · Aug 18, 2025
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
Cosmos Health CEO Greg Siokas has increased his stake in the company by acquiring over 1.4 million shares worth $526,000 in the past week, and over 2.7 million shares worth $1.3 million in the past five months, demonstrating his confidence in the company's future.
GlobeNewswire Inc. · Apr 30, 2025
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
Virax Biolabs has extended its exclusive distribution agreement with Cosmos Health to commercialize Mpox Virus Real-Time PCR Detection Kits in the Gulf Cooperation Council countries. The kits have high sensitivity and specificity and can deliver results in under 70 minutes.
Benzinga · Sep 16, 2024
Cosmos Health secures new pharma manufacturing deals - Investing.com
Cosmos Health's subsidiary Cana Laboratories has expanded its contract manufacturing portfolio with additional agreements with Provident Pharmaceuticals, involving the production of several pharmaceutical products.
Investing.com · Jul 18, 2024
Cosmos Health subsidiary secures Australian CBD product deal By Investing.com - Investing.com
Cosmos Health's subsidiary Cana Laboratories has entered into a contract manufacturing agreement with Australia's Humacology to produce up to 500,000 units of Humacology's CBD products. This follows Cana's recent deal with Provident Pharmaceuticals to manufacture 4.32 million units of a vitamin D product, highlighting Cosmos Health's focus on expanding its high-margin contract manufacturing business.
Investing.com · Jul 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CO
COSM
Cosmos Holdings Inc. Common Stock
Buy
Sell
Market
Limit
Soon
COSM
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any COSM yet.
Related Tickers
Earnings